All the Active Ingredient Drugs
DPP-4 Inhibitor, SGLT2 Inhibitor. Empagliflozin 10, 25 mg, Linagliptin 5 mg. F.C.TABS.: 30. The recomm. dose of this drug is 10 mg empagliflozin/5 mg linagliptin once dly. in the morn., taken with/ without food. In pts. tolerat. this formul., the dose may be incr. to 25 mg empagliflozin/5 mg linagliptin once dly. See lit.
Indic. as an adjunct to diet and exercise to improve glycem. control in adults with type 2 diab. mell. when tmt. with both empagliflozin and linagliptin is approp..
C/I: Sev. ren. impair., end-stage renal dis., or dialysis. Hist. of hypersens. reaction to linagliptin, such as anaphylax., angioedema, exfoliative skin condit., urticaria, or bronch. hyperreactivity. Hist. of serious hypersens. reaction to empagliflozin.
DPP-4 Inhibitor. Linagliptin 5 mg. F.C. TABS: 30. 5 mg ×1/d with /without
As an adjun. to diet & exercise to improve
glycem. control in adult. with type 2 diab.
mell. Should not be used in pts. with type
1 diabet. or for the tmt. of diab.
ketoacidosis, as it would not be effect. in
The drug has not been studied in pts.
with a hist. of pancreatit. It is unknown
whether pts. with a hist. of pancreatit. are
at an incr. risk for the develop. of
pancreatit. while using the drug.
C/I: Hypersens. to act. subst. (anaphylaxis, angioedema, exfoliative
skin condit., urticaria, or bronch.
Biguanide, DPP-4 Inhibitor. Linagliptin 2.5 mg, Metformin Hydrochloride 500, 850, 1000 mg. F.C TABS: 14, 60 x 2.5 mg linagliptin/500 mg metformin, 2.5 mg linagliptin/ 850 mg metformin, 2.5 mg linagliptin/1000 mg metformin. Should be individualized based on effective. and tolerability. Take 2 x dly. with meals. Pts current. not treated with metformin: init. 2.5 mg linagliptin/500 mg metformin 2 x dly. Pts already treated with metformin: take tabs. with same dly. dose of metf. divided 2 x dly. Pts treated with both ingredients separat.: switch to tabs contain. same dose of each ingredient. See lit.
Adjunct to diet and exercise to improve glycem. control in adults with type 2 diabetes mellitus when tmt. with both linagliptin and metformin is appropr. should not be used in pts with type 1 diabetes or
for tmt. of diabetic ketoacidosis. not been studied in pts with a history of pancreatitis.
C/I: Renal impair. (e.g., serum creat.≥1.5 mg/dL for men, ≥1.4 mg/dL for women/ abnormal CrCl) which may also result from conditions such as cardiovasc. collapse (shock), acute MI., and septicemia. Acute or chron. metabolic acidosis, includ. diabetic ketoacidosis, hist. of hypersens. react. to linagliptin, such as anaphylaxis, angioedema, exfoliative skin cond., urticaria, or bronchial hyperreactivity, hypersens. to metformin.